首页> 外文期刊>Oncology Research >Silencing of LIM and SH3 Protein 1 (LASP-1) Inhibits Thyroid Cancer Cell Proliferation and Invasion
【24h】

Silencing of LIM and SH3 Protein 1 (LASP-1) Inhibits Thyroid Cancer Cell Proliferation and Invasion

机译:LIM和SH3蛋白1(LASP-1)的沉默抑制甲状腺癌细胞增殖和侵袭

获取原文
获取原文并翻译 | 示例
       

摘要

LIM and SH3 protein 1(LASP-1) is a specific focal adhesion protein that was first identified in breast cancer and then reported to be involved in cell proliferation and migration. Many studies have demonstrated the essential role of LASP-1 in cancer progression. However, there have been no studies on the association of LASP-1 with thyroid cancer. In this study, we investigated the expression pattern and biological function of LASP-1 in thyroid cancer. We found that LASP-1 was highly expressed in thyroid cancer tissues and cell lines. LASP-1 silencing had antiproliferative and anti-invasive effects on thyroid cancer cells. Moreover, tumor xenograft experiments showed that LASP-1 silencing suppressed thyroid cancer cell growth in vivo. We also demonstrated that LASP-1 silencing decreased the protein expression of p-PI3K and p-Akt. In conclusion, these findings suggest LASP-1 to be an oncogene and a potential therapeutic target in thyroid cancer.
机译:LIM和SH3蛋白1(LASP-1)是首先在乳腺癌中鉴定的特异性焦粘连蛋白,然后据报道参与细胞增殖和迁移。 许多研究表明Lasp-1在癌症进展中的基本作用。 然而,没有关于LASP-1与甲状腺癌的关联的研究。 在这项研究中,我们研究了LASP-1在甲状腺癌中的表达模式和生物学功能。 我们发现LASP-1在甲状腺癌组织和细胞系中高度表达。 LASP-1沉默对甲状腺癌细胞进行了抗增殖和抗侵袭作用。 此外,肿瘤异种移植实验表明,LASP-1沉默抑制体内甲状腺癌细胞生长。 我们还证明LASP-1沉默降低了P-PI3K和P-AKT的蛋白质表达。 总之,这些研究结果表明Lasp-1是甲状腺癌中的癌基因和潜在的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号